K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaMicroRNAs: control and loss of control in human physiology and diseaseMesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerRecent progress in pancreatic cancerGenetic mutations associated with cigarette smoking in pancreatic cancerWhat is the origin of pancreatic adenocarcinoma?The role of transgenic mouse models in carcinogen identificationPancreatic Cancer from Molecular Pathways to Treatment OpinionMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesHeterogeneity and targeting of pancreatic cancer stem cellsInterplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesisSomatic mutations in exocrine pancreatic tumors: association with patient survivalGenetic factors affecting patient responses to pancreatic cancer treatmentKRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreasEnhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoproteinAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationThe immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of originPathology and molecular genetics of pancreatic neoplasms.Pancreatic adenocarcinoma: epidemiology and genetics.MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer casesComparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancerEpigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsPancreatic cancer: any prospects for prevention?A rapid PCR ELISA for the detection of activated K-ras in colorectal cancer.KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced ApoptosisMolecular signatures of pancreatic cancer.Genetic progression in the pancreatic ducts.Clinical relevance of KRAS in human cancers.In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.Chemoprevention strategies for pancreatic cancerComplex role for the immune system in initiation and progression of pancreatic cancer.Ras in cancer and developmental diseasesThe molecular targets for the diagnosis and treatment of pancreatic cancer.Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis.
P2860
Q21129230-2F30857E-3757-43D6-86E9-AD4C65CBB623Q24618771-66918C85-B0D2-443E-84D7-0F3044448066Q24622837-84E11C32-5D80-4C62-936E-E689869FA64BQ24626346-6B67B981-B2E1-4115-A666-A4919BA7CFD7Q24658185-FE92D12C-0F2A-45FE-943F-77DDB03E947BQ24805751-2B01916C-045F-4C1D-93C1-C20ACBCB9222Q24814156-0992C1BA-E2C7-497F-826A-A1F02E0292CDQ26743482-BE284122-B41B-49CD-AD6E-79606715C7B0Q26774636-D00C6385-68AE-42E5-A415-16E326138E10Q26828959-360CDDBC-D7C9-4526-9360-C3B18E717C2DQ26851734-7275E435-E648-4D17-A2E3-415503A299FEQ26996794-1F33994E-E8D8-4DF4-B473-EC56325468F4Q27852155-B134545B-E116-4811-B7A4-BF294C342170Q28075293-F65A35E2-F94C-447B-A0A7-9441B6955B8CQ28289209-D5ED3438-FBDA-4FAF-B6F7-F0F859AF7732Q28383234-C6285B5A-2E95-4DB8-A2F2-B550AF2F2541Q28730199-9090839A-F229-4E96-A3B1-7CE690F1D8E1Q30414395-5720F8EF-9C45-47FA-BDCE-494A49EE897FQ33404952-4EA824EF-8924-4B0F-BD7D-86E1B40C4F61Q33408107-23CEB55D-BBF9-4B14-9A40-6C654AEB7EA7Q33581119-F8FD4655-E1B6-4823-845E-788A0D37D2A6Q33677968-8C115E6D-A3FB-4431-9C9B-4A39689197FDQ33750187-DDF1C520-E829-4442-AB1C-1ABE595A6414Q33798878-D3B17786-0018-4B49-A63A-F14715C2197FQ33801377-22CAA28B-78FF-4AFA-823E-DE38E6DC7398Q33806821-BB09B1FE-6055-4215-BE6A-B9B7257FDBDCQ33838925-DD85E581-8AC5-4279-9E9E-CB5BBF333933Q33878516-8FD5F438-967D-466A-B67C-E0EA9EDF9052Q33887648-7526E58E-A698-44C6-A2FA-E946B88E785EQ33915871-E49A7E5E-E7A7-43B9-807F-76476811A20AQ33918801-4CC43391-361D-4C21-B027-DD8DE2DB200CQ33943167-07BD1CD2-6A40-44A0-AF0F-B97EAD3B3392Q33959887-E73B3C7A-AB39-4AC4-9C8E-6C089A54AE12Q34037704-DBB02DDC-14F1-4B5B-8F8C-4E0D98256503Q34061112-F12058F8-99A4-47FB-8E80-471F907FDD7CQ34082960-9E6A33FD-CA74-49DE-8515-5A7134D0D31AQ34093784-0359E58A-9063-454B-85B1-A0B184FF75BAQ34202697-1952C1C6-F6A0-4315-8670-626DA4FAAFCFQ34494019-69F208BA-357A-473D-89E7-D81EB6D9FB02Q34542045-7C0E14C4-EC1B-42B2-80B5-69A113149C4A
P2860
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@ast
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@en
type
label
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@ast
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@en
prefLabel
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@ast
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@en
P2093
P2860
P1476
K-ras oncogene activation in a ...... oligonucleotide hybridization.
@en
P2093
Allison DC
Cameron JL
Goodman SN
Kensler TW
Offerhaus GJ
van Mansfeld AD
van Weering DH
P2860
P304
P407
P577
1993-08-01T00:00:00Z